Evoke Stockholders Received $11.00 Per Share in Cash SOLANA BEACH, Calif., and VERO BEACH, Fla., Dec. 17, 2025 /PRNewswire/ -- Evoke Pharma, Inc. (formerlyNASDAQ: EVOK) ("Evoke") and QOL Medical, LLC ("QOL Medical") today announced that the tender offer (the "Offer") by QOL-EOS Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of QOL Medical (the "Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the "Shares"), of Evo

AUSTIN, Texas and TOKYO, Dec. 17, 2025 /PRNewswire/ -- According to DataM Intelligence, the global Disease-Modifying Therapies (DMTs) Market was valued at USD 65.32 billion in 2024 and is projected to reach USD 112.64 billion by 2033, expanding at a CAGR of 6.2% during the forecast period 2025–2033. This steady yet structurally important growth reflects a fundamental transformation in chronic disease management. Healthcare systems are increasingly shifting from symptom-focused treatment towa

2025年11月11日，国家药品监督管理局正式批准齐鲁制药神经节苷脂钠注射液（商品名：申捷®）用于治疗急性缺血性脑卒中（AIS）的新适应症。 此次获批，标志着该产品在脑血管疾病治疗领域的应用迈向了以高级别循证医学证据为基础、以精准适应症为导向的新阶段，为临床医生和患者提供了新的治疗武器。 FOCUS研究证实 神经节苷脂可显著改善 急性缺血性卒中患者远期预后 ﹀ 申捷®（单唾液酸四己糖神经节苷脂钠，GM1）治疗急性缺血性卒中（AIS）的随机、双盲、安慰剂对照III期研究（FOCUS研究），由南京大学医学院附属鼓楼医院徐运教授牵头，在全国68家中心开展。该研究纳入1232例受试者。其严谨的设计、充足的受试者样本量为科学验证药物的疗效与安全性提供高级别循证医学依据。 在2025年世界卒中大会（WSC）上，FOCUS研究结果在Plenary, Award &. Late Breaking Session进行了报告。Plenary, Award & Late Breaking Session是WSC学术交流核心环节，专门呈现最新临床研究成果或突破性技术。受该研究的全国leading PI南京大学

今天，罗氏诊断阿尔茨海默病（Alzheimer\x26#39;s Disease, AD）脑脊液（CSF）系列检测获国家药品监督管理局（NMPA）批准正式在华上市，这是国内首个神经领域荣获优先审评资格的体外诊断产品，也是目前国内唯一获批可用于临床诊断的AD CSF系列检测。 这一里程碑式的进展有望帮助临床更早、更精准地识别AD患者，加速构建中国AD早诊早治新生态。（来源:罗氏诊断官微）

Lotus Neuro builds on Insightec's groundbreaking focused ultrasound platform to accelerate next-generation brain therapies globally, with funding from Nexus NeuroTech Ventures. MIAMI and HAIFA, Israel, Dec. 17, 2025 /PRNewswire/ -- Insightec, a global healthcare innovator pioneering the use of focused ultrasound to transform patient care, today announced the spin-out and launch of Lotus Neuro, a new clinical stage biotechnology company advancing the next generation of brain‑targeted therapeutics

PHILADELPHIA, Dec. 17, 2025 /PRNewswire/ -- In 2025, MOBILion Systems achieved a decisive technical milestone through proof-of-concept demonstration that high-resolution ion mobility (HRIM), operated in MOBILion's unique PAMAF mode, fundamentally reshapes mass-spectrometry-based proteomics. This work empirically demonstrates what the field has theorized for more than two decades and does so in a way existing technologies are unable to match. More than 25 years ago, leading experts identified a f

With federal regulators intensifying scrutiny of PBM practices and employers facing mounting ERISA and CAA-2021 fiduciary exposure, the need for a fiduciary compliant, conflict-free pharmacy benefits model has never been more urgent. US-Rx Care— the nation's first fiduciary PBM—delivers a legally aligned, clinically rigorous, and financially transparent alternative that consistently reduces plan and member costs by 30–50%. HOLLYWOOD, Fla., Dec. 17, 2025 /PRNewswire/ -- A wave of federal scrutiny

ASPIRE pivotal IDE study results demonstrated PearlMatrix achieved superior clinical success and superior time-to-fusion at 24 months compared to local autograft. The rigor of the ASPIRE study reflects unmatched clinical design and results including: - More than twice as many patients fused at 6 months - Approximately 60% high-risk patients - As safe as local autograft WESTMINSTER, Colo., Dec. 17, 2025 /PRNewswire/ -- Cerapedics Inc., a global, commercial-stage orthopedics company dedicated to

SALT LAKE CITY, Dec. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19. The analysis showed a high homology against 3,900 influenza sequences, confirming comparable reacti

Study demonstrated clear target engagement at both tested doses Potential for THRV-1268 to address prolonged QTcF in cardiometabolic diseases Phase 2a ASPIRE-HF study to commence enrollment in 2026 MONTREAL, Dec. 17, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias and cardiometabolic diseases, today announced encouraging results from a recently comple